Latest News
Cambridge, Massachusetts, USA. 17 August, 2021. Seroba’s portfolio company, Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to […]
Hamilton, Ontario and Boston, Massachusetts. July 28, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has […]
Galway, Ireland. 15 July 2021. Seroba portfolio company, Palliare, an emerging company with the vision to create a safer operating room, has announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends […]
Paris, France – 21st July 2021. • Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases • Funding led by Seroba […]
Galway, Ireland. 28 June 2021. Palliare, an emerging company with the vision to create a safer operating room, has announced the closing of an oversubscribed $8 million Series A funding round. The round was led by […]
Alcester, England & Beverly, Mass., USA. June 23, 2021. Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today that it […]
Hamilton, Ontario and Boston. June 14, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion […]
Hamilton, Canada and Boston, USA. May 6, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration […]
Clonmel, Ireland. April 23, 2021. Seroba’s portfolio company, Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application […]
Dublin, Ireland. 14 April 2021. Seroba’s portfolio company, PQ Bypass Inc., a medical device pioneer advancing the treatment of complex peripheral artery disease (PAD), has been acquired by Endologix, a global medical device company wholly owned […]
